The Pharma Data

JANUARY 17, 2021

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), a leader in the development of transdermal and sublingual drug formulations reported significant advancements in four therapeutic development programs. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp. Forward looking statements.

Production 40

Production Drug Delivery Development Drugs 40

The Pharma Data

JANUARY 27, 2021

In 2020, XPhyto confirmed successful activation of its peptide-based biosensor program when delivered using Vektor’s sublingual drug delivery platform. Further, Vektor is currently engaged in the development of a sublingual drug formulation for a major European generic drug company.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

The Pharma Data

DECEMBER 17, 2020

In addition, TLC is preparing for scale-up production of TLC590, as for complex lipid products, the manufacturing process and batch size used in pivotal clinical trials and New Drug Application submission must be the same as future commercial batches. Cautionary Note on Forward-Looking Statements. Source link.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Containment 40

XTalks

AUGUST 30, 2022

The pharmaceutical industry deals with threats such as product liability, cyberthreats, supply chain disruptions, competition from generic drugs and more. Although these leadership styles are of very different natures, they also contain some commonalities. Therefore, strategic intent is vital when making decisions.

Life Science 105

Life Science Generic Drugs Drug Delivery Compliance 105